US20080233603A1 - Fluorine NMR spectroscopy for biochemical screening - Google Patents
Fluorine NMR spectroscopy for biochemical screening Download PDFInfo
- Publication number
- US20080233603A1 US20080233603A1 US11/825,779 US82577907A US2008233603A1 US 20080233603 A1 US20080233603 A1 US 20080233603A1 US 82577907 A US82577907 A US 82577907A US 2008233603 A1 US2008233603 A1 US 2008233603A1
- Authority
- US
- United States
- Prior art keywords
- enzyme
- substrate
- protein
- peptide
- nmr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000005481 NMR spectroscopy Methods 0.000 title abstract description 25
- 238000012216 screening Methods 0.000 title abstract description 18
- 229910052731 fluorine Inorganic materials 0.000 title description 5
- 239000011737 fluorine Substances 0.000 title description 4
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 title description 3
- 239000000758 substrate Substances 0.000 claims abstract description 49
- 238000000034 method Methods 0.000 claims abstract description 44
- 108091000080 Phosphotransferase Proteins 0.000 claims abstract description 6
- 102000020233 phosphotransferase Human genes 0.000 claims abstract description 6
- 102000004190 Enzymes Human genes 0.000 claims description 30
- 108090000790 Enzymes Proteins 0.000 claims description 30
- 238000006243 chemical reaction Methods 0.000 claims description 29
- 239000000203 mixture Substances 0.000 claims description 24
- 239000003112 inhibitor Substances 0.000 claims description 21
- 108091005804 Peptidases Proteins 0.000 claims description 5
- 239000004365 Protease Substances 0.000 claims description 5
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 claims description 4
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 claims description 4
- 102000003960 Ligases Human genes 0.000 claims description 3
- 108090000364 Ligases Proteins 0.000 claims description 3
- 102000001253 Protein Kinase Human genes 0.000 claims description 3
- 239000000556 agonist Substances 0.000 claims description 3
- 108060006633 protein kinase Proteins 0.000 claims description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 2
- 238000002372 labelling Methods 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 abstract description 28
- 108090000623 proteins and genes Proteins 0.000 abstract description 28
- 150000001875 compounds Chemical class 0.000 abstract description 26
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 abstract description 12
- 238000013537 high throughput screening Methods 0.000 abstract description 12
- 101000779418 Homo sapiens RAC-alpha serine/threonine-protein kinase Proteins 0.000 abstract description 11
- 230000026731 phosphorylation Effects 0.000 abstract description 9
- 238000006366 phosphorylation reaction Methods 0.000 abstract description 9
- 238000002474 experimental method Methods 0.000 abstract description 8
- 238000001514 detection method Methods 0.000 abstract description 5
- 238000004293 19F NMR spectroscopy Methods 0.000 abstract description 4
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 abstract description 4
- 238000003366 endpoint assay Methods 0.000 abstract description 3
- 238000002825 functional assay Methods 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 43
- 235000018102 proteins Nutrition 0.000 description 26
- 239000000126 substance Substances 0.000 description 17
- 238000001228 spectrum Methods 0.000 description 14
- 238000006911 enzymatic reaction Methods 0.000 description 11
- 102000004142 Trypsin Human genes 0.000 description 10
- 108090000631 Trypsin Proteins 0.000 description 10
- 239000012588 trypsin Substances 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 9
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 7
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 7
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 125000001153 fluoro group Chemical group F* 0.000 description 4
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 4
- 108010052968 leupeptin Proteins 0.000 description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 101000797997 Xenopus laevis RAC-alpha serine/threonine-protein kinase Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000010256 biochemical assay Methods 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102100027940 Serine/threonine-protein kinase PAK 4 Human genes 0.000 description 2
- 101710148155 Serine/threonine-protein kinase PAK 4 Proteins 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000002875 fluorescence polarization Methods 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000004853 protein function Effects 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000002821 scintillation proximity assay Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- GWCHTTSPSUWRBA-UHFFFAOYSA-N 3-chloro-1h-quinolin-4-one Chemical compound C1=CC=C2C(O)=C(Cl)C=NC2=C1 GWCHTTSPSUWRBA-UHFFFAOYSA-N 0.000 description 1
- RWXZXCZBMQPOBF-UHFFFAOYSA-N 5-methyl-1H-benzimidazole Chemical compound CC1=CC=C2N=CNC2=C1 RWXZXCZBMQPOBF-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 1
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 238000010640 amide synthesis reaction Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003297 denaturating effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000004401 flow injection analysis Methods 0.000 description 1
- 238000000806 fluorine-19 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- ZBCGBIZQNMVMPC-UHFFFAOYSA-N methyl isoquinoline-3-carboxylate Chemical compound C1=CC=C2C=NC(C(=O)OC)=CC2=C1 ZBCGBIZQNMVMPC-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- VEFJHAYOIAAXEU-UHFFFAOYSA-N okadaic acid Natural products CC(CC(O)C1OC2CCC3(CCC(O3)C=CC(C)C4CC(=CC5(OC(CC(C)(O)C(=O)O)CCC5O)O4)C)OC2C(O)C1C)C6OC7(CCCCO7)CCC6C VEFJHAYOIAAXEU-UHFFFAOYSA-N 0.000 description 1
- QNDVLZJODHBUFM-WFXQOWMNSA-N okadaic acid Chemical compound C([C@H](O1)[C@H](C)/C=C/[C@H]2CC[C@@]3(CC[C@H]4O[C@@H](C([C@@H](O)[C@@H]4O3)=C)[C@@H](O)C[C@H](C)[C@@H]3[C@@H](CC[C@@]4(OCCCC4)O3)C)O2)C(C)=C[C@]21O[C@H](C[C@@](C)(O)C(O)=O)CC[C@H]2O QNDVLZJODHBUFM-WFXQOWMNSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 108010058266 p21-Activated Kinases Proteins 0.000 description 1
- 102000006271 p21-Activated Kinases Human genes 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000002805 secondary assay Methods 0.000 description 1
- 238000010517 secondary reaction Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000003384 small molecules Chemical group 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- MYMLGBAVNHFRJS-UHFFFAOYSA-N trifluoromethanamine Chemical compound NC(F)(F)F MYMLGBAVNHFRJS-UHFFFAOYSA-N 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
Definitions
- NMR Nuclear Magnetic Resonance
- the present invention provides a method for identifying kinase inhibitors using NMR technology. In another aspect, the present invention provides kinase inhibitors identified by NMR technology.
- the present invention also provides a NMR method to characterize the unknown function of a protein by its interaction with CF 3 -labeled substrates of other known-function proteins.
- FIG. 1 provides 19 F 564 MHz NMR spectra for the CF 3 —CO N-capped-AKTide as a function of time (indicated in minutes) after the beginning of the enzymatic reaction.
- the activated protein, the peptide and ATP concentration were 50 nM, 30 ⁇ M and 131 ⁇ M, respectively.
- WtAKT1 recombinant protein was produced by infection of Sf21 insect cells with baculovirus coding for the full length protein fused to the GST moiety at the N-terminus and then purified to homogeneity after removal of the GST tag.
- the samples were in 50 mM Tris pH 7.5, with 1 mM DTT and 5 mM MgCl 2 . Spectra were recorded at 20° C.
- FIG. 2 provides ( FIG. 2A top) 19 F 564 MHz NMR spectra for the CF 3 —CO N-capped-AKTide recorded with three different concentrations (indicated in ⁇ M) for ATP.
- the activated protein and the peptide concentrations were 40 nM and 30 ⁇ M, respectively.
- the samples were in 50 mM Tris pH 7.5, with 1 mM DTT and 5 mM MgCl 2 .
- the reaction was run at 22° C. and quenched after 60 minutes with the addition of 10 ⁇ M staurosporine.
- FIG. 2B bottom Integral of the phosphorylated peptide as a function of the ATP concentration and the best fit of the experimental data with the derived KM for ATP of 89+/ ⁇ 17 ⁇ M.
- FIG. 3 provides ( FIG. 3A top) 19 F 564 MHz NMR spectra for the CF 3 —CO N-capped-AKTide recorded with three different concentrations (indicated in ⁇ M) for the inhibitor H89.
- the activated protein, the peptide and ATP concentration were 40 nM, 30 ⁇ M and 131 ⁇ M, respectively.
- the samples were in 50 mM Tris pH 7.5, with 1 mM DTT and 5 mM MgCl 2 . The reaction was run at 22° C. and quenched after 120 minutes with the addition of 10 ⁇ M staurosporine.
- FIG. 3B bottom Integral of the phosphorylated peptide as a function of the inhibitor concentration and the best fit of the experimental data with the derived IC 50 for H89 of 0.72+/ ⁇ 0.05 ⁇ M.
- FIG. 4 provides the screening of proteases, where the substrate is the peptide of Seq ID NO:2 and the protein is trypsin from bovine pancreas.
- PMSF phenylmethylsulfonyl fluoride
- the reaction was performed in the absence of compound (b), in the presence of a five compound mixture (2-amino-6 methylquinazolin-4 ol, ethyl 2-quinoxalinecarboxylate, 5-methyl-benzimidazole, methyl isoquinoline-3-carboxylate, and leupeptin) (c), in the presence of the same mixture without leupeptin (d), and in the presence of only leupeptin (e).
- the protein, peptide, and compound concentrations were 15 nM, 30 ⁇ M, and 20 ⁇ M, respectively.
- a total of 128 scans with 2.8 s repetition time were recorded for each spectrum (6 minute measuring time).
- Pep and C-pep are the substrate and the product respectively.
- the asterisks in (c) and (e) indicate the chemical shift of the missing cleaved peptide signal.
- FIG. 5 provides the 19F spectra of the peptide of Seq ID NO:2 in the presence of three different proteins, 25 nM AKT1 ( FIG. 5A top), 15 nM trypsin ( FIG. 5B middle) and 150 nM PAK-4 ( FIG. 5C bottom).
- the peptide is a good substrate for AKT1 and trypsin.
- the chemical shift of the cleaved peptide is quite different when compared to the chemical shift of the phosphorylated peptide.
- the reaction performed in the presence of p-21 activated protein PAK-4 results in the appearance of a signal at the chemical shift of the phosphorylated peptide.
- the present invention overcomes the limitations of NMR biochemical screening with respect to protein and substrate concentrations when compared to prior art HTS techniques.
- the present invention provides a novel and sensitive NMR method in which a moiety with three fluorine atoms (CF 3 ) is used to label a substrate.
- CF 3 fluorine atoms
- the use of a CF 3 -labeled substrate, e.g., a CF 3 -labeled peptide allows for rapid and reliable biochemical screening at protein and substrate concentrations comparable to the concentrations utilized by standard HTS techniques.
- the NMR method of the present invention has unique advantages. i) Fluorine NMR spectroscopy is very sensitive, 0.83 times that of the proton.
- Fluorine signals appear as sharp singlet resonances (the experiments do not require proton decoupling if the CF 3 is not scalar coupled to protons) originating from three fluorine atoms, and therefore, the signal is very intense. This property is crucial for the screening because it permits the use of substrate concentrations that are in the range of its K m thus allowing detection of medium and weak inhibitors iii) There are no spectral interferences from protonated solvents, buffers, or detergents typically used in enzymatic reactions.
- NMR has been utilized to measure the phosphorylation of a CF 3 -labeled substrate by the protein Ser/Thr kinase AKT1.
- Protein kinase AKT1 is an anti-apoptotic protein kinase that has an elevated activity in a number of human malignancies [Staal, S. P. et al. J. Exp. Med. 167, 1259-1264 (1988); Bellacosa, A. Et al. Science 254, 274-277 (1991)].
- the substrate AKTide is a peptide of 14 aminoacids [Obata, T. et al. J. Biol. Chem.
- the CF 3 at the N terminal, the C terminal or the substituted amino acid (the para-CF 3 Phe points toward the solvent, while the Ser to be phosphorylated points toward the enzyme), is located away from the serine phosphorylation site and therefore does not interfere with the binding.
- chemical synthesis is required for the introduction of the CF 3 moiety in the appropriate position in the substrate.
- the sum of the two integral signals at any time after the start of the reaction corresponds to the signal integral of the unphosphorylated peptide at time 0.
- the enzymatic reaction is complete after 149 minutes and only the signal of the phosphorylated peptide is visible in the spectrum.
- the reaction can also be carried out in the presence of a mixture of compounds containing an inhibitor. Then, deconvolution of the active mixture is performed to identify which of the compounds in the mixture is the inhibitor.
- deconvolution means that the reaction is performed repeatedly in the presence of the mixture and in the absence of each one of the compounds. That is, there is no inhibition when the reaction in is carried out in the presence of the mixture minus the inhibitory compound. To confirm the inhibitory effect of one of the compounds, inhibition can be observed when the reaction is also performed in the presence of the single inhibitory compound that was identified from the mixture.
- the reaction of unphosphorylated CF3-labeled peptide of Seq ID NO:1, ATP, and activated protein kinase AKT1 was also performed in the presence of a five molecule mixture containing the compound H89 [Reuveni, H. et al. Biochemistry 41, 10304-10314 (2002)], an AKT1 inhibitor.
- the result was inhibition of peptide phosphorylation.
- the inhibitory effect over peptide phosphorylation of H89 was confirmed when the reaction was performed in the presence of only H89.
- the reaction is typically stopped after an established delay that will depend on the enzyme and ATP concentrations and K cat .
- the reaction can be quenched either by adding a concentrated solution of EDTA or by denaturating the protein.
- a more economical method is employed to quench reaction, namely the addition of about 5 to about 10 ⁇ M of the strong inhibitor staurosporine (IC 50 in the low nM range). Even after several hours from the addition of staurosporine no changes of the 19 F spectrum were observed. After the quench, the signal intensity ratio of the two 19 F signals is monitored.
- the dissociation binding constant of ATP must be calculated first in order to optimize the ATP concentration used for the screening experiments and for deriving the binding constant of the hits from their IC 50 .
- reactions at different ATP concentrations are recorded [Fersht, A. Enzyme Structure and Mechanism, W.H. Freeman and Company, New York 1985].
- the signal intensity of the phosphorylated peptide as a function of the ATP concentration is shown in FIG. 2 . Fitting of the experimental data results in a binding constant for ATP (in the presence of 30 ⁇ M substrate) of 89+/ ⁇ 17 ⁇ M.
- screening is first performed at a single concentration for the compounds in the library.
- Compounds can be screened in small or large mixtures. For example, if only strong inhibitors with IC 50 ⁇ 5 ⁇ M will be considered, then it will be sufficient to use molecules at about a 5 ⁇ M concentration.
- the reliability of the method of the present invention allows the identification of a weaker inhibitor with, e.g., an IC 50 in the range of 10-20 ⁇ M even when the concentration of the screened molecules is only about 5 ⁇ M.
- substrate concentrations can be as low as about 10-20 nM. This low concentration allows the preparation of mixtures with a large number of components without severe problems of aggregation or solubility.
- Deconvolution of the active mixture is then carried out for the identification of the inhibitor.
- experiments at different inhibitor concentrations are then performed as shown in FIG. 3 for the compound H89 [Reuveni, H. et al. Biochemistry 41, 10304-10314 (2002)].
- a CF 3 -labeled ATP analogue can also be used with the method of the present invention. In this case, the 19 F signals of ATP and ADP are monitored.
- Inhibitors that bind in the ATP binding pocket or inhibitors that compete with the peptide for the substrate binding site can be identified.
- the method of the present invention therefore represents a simple and reliable assay because it is homogeneous and directly detects both the phosphorylated and unphosphorylated substrate.
- the 19 F NMR assay does not require i) the presence of secondary reactions performed with enzymes or specific antibodies or ii) separation and/or washing steps necessary for the readout with other methods.
- the method's simplicity results in reliable lead molecule identification and quantification of the molecules' inhibitory activity.
- Compounds displaying only a weak inhibitory activity can also be safely selected. Small chemical changes of the weak inhibitors or the selection of similar molecules bearing the same scaffold might result in the identification of potent inhibitors.
- the method of the present invention is not limited to the identification of inhibitors only, but can also be used for the detection of agonists.
- the 19 F signal of the phosphorylated peptide in the presence of an agonist is larger when compared to the same signal of the reference sample (i.e. sample for which the reaction was performed in the absence of compounds to be screened).
- the concentration of the protein used with this method can be as low as a few nanomolar, comparing favorably with the concentration used in other HTS techniques.
- the volume necessary for each NMR sample using a 5 mm probe is about 500-550 ⁇ L.
- a 2- to 3-fold volume reduction is achieved in accordance with the present invention with the use of a flow-injection probe or a 3 mm probe.
- the high sensitivity of the CF 3 signal allows for rapid acquisition of the spectra. Further, the same spectra can be recorded even more rapidly with the use of cryogenic technology applied to 19 F detection. Therefore, under the settings of the current method, the spectra that require an acquisition time of 3 minutes can be recorded in just 12 seconds. Further, the problems of radiation damping encountered in proton-detected experiments recorded with cryoprobes are absent in the fluorine-detected methodology of the present invention because of the low concentration of the CF 3 -labeled substrate.
- Bovine serum albumin can be used with the method of the present invention to avoid sticking of the protein to the tube wall [Hlady, V. et al. Curr. Opin. Bioctechnol. 7, 72-77 (1996)].
- BSA Bovine serum albumin
- HSA human serum albumin
- the method of the present invention can also be applied to many different types and subtypes of enzymes (e.g. proteases, phosphatases, ligases, etc.).
- the screening can be performed with trypsin, a protease that cleaves peptide bonds C-terminally of lysine and arginine [Price, N. C. et al. Fundamentals of Enzymology, Oxford University Press, Oxford, U.K. (1999)], and, as a substrate, the peptide (ARKRERAF(3-CF 3 )SFGHHA) (Seq ID NO:2). As shown in FIG.
- Another application of the method of the present invention is the determination of protein function.
- proteins In view of the ready availability of high-throughput genome sequencing, thousands of proteins have been identified. However, the function of many of these proteins is unknown.
- the function of the protein can be inferred from the types of substrates that can be modified.
- a functional genomic library of CF 3 -labeled substrates of enzymes of known function is generated. These substrates are first tested on their known respective enzymes to determine the 19 F chemical shifts of the starting and modified substrate. Some substrates can act as substrates for different classes of enzymes.
- This library of substrates is then screened as single compounds or in small mixtures against the protein with unknown function. The reduction in signal intensity of a 19 F signal and the appearance of a new resonance at a defined chemical shift allows the recognition of the protein function.
- the speed of the enzymatic reaction of PAK4 is only 1/22 of the speed of AKT1, therefore, the period of time for the reaction in the presence of PAK4 was longer than the period of time for the reaction in the presence of AKT1.
- the method of the present invention is also applicable to activated enzymes.
- the method of the present invention extends the capabilities of NMR to the enzymatic reactions performed by Ser/Thr kinases.
- the method performs well and provides a reliable array of experimental data.
- WtAKT1 recombinant protein were produced by infection of sf21 insect cells with baculovirus coding for the full length protein fused to GST at the N-terminus.
- the cells were treated with okadaic acid for 4 hours prior to harvesting. This treatment, by inhibiting the cellular phosphatases, increaseed the total phosphorylation level of the protein leading to the phosphorylation of the two sites critical for AKT activity, threonine 308 in the activation loop and serine 473 in the C terminal hydrophobic motif. Lysis, purification, and removal of the GST tag were performed by following standard procedures. Trypsin, purchased from Roche Molecular Biochemical (Cat. No. 1418025), was dissolved in 1% acetic acid solution at a final stock solution concentration of 8.33 ⁇ M.
- the serine/threonine p21-activated kinase PAK4 was expressed as a GST fusion protein in Escherichia coli and purified to homogeneity after removal of the GST tag.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
Abstract
High-Throughput Screening (HTS) of large compound libraries is the method of drug-lead discovery. It is now well accepted that for a functional assay, quality is more important than quantity. A biochemical NMR method originally proposed by Percival and Withers (Biochemistry, 1992, 31, 498-505) is extended to the screening of Ser/Thr kinases. The method requires the presence of a CF3 (or CF) moiety on the substrate and utilizes 19F NMR spectroscopy for the detection of the starting and enzymatically modified substrates. Experiments can be performed in real time or in an endpoint assay format using protein and substrate concentrations comparable to the ones used by other HTS techniques. Application of this technique to the phosphorylation of a substrate by the protein Ser/Thr kinase AKT1 is presented.
Description
- The present application is a divisional of copending application Ser. No. 10/888,378 filed on Jul. 9, 2004, which claims benefit of U.S. Provisional Application No. 60/486,099 filed Jul. 10, 2003.
- The testing of a large number of molecules in an appropriate biochemical or cellular assay is usually one of the first steps in a drug discovery project [Smith A. Nature 418, 453-459 (2002)]. Screening based on Fluorescence Polarization (FP) [Checovich, W. J. et al. Nature 375, 254-256. (1995); Pope, A. J. et al. Drug Discov.
Today 4, 350-362 (1999)], Fluorescence Resonance Energy Transfer (FRET), Homogeneous Time-Resolved Fluorescence (HTRF) and the traditional Scintillation Proximity Assay (SPA) are nowadays the technologies of choice for a biochemical assay [Parker, G. J. et al. J. Biomol.Screening 5, 77-88 (2000)]. The sensitivity and miniaturized format of these methodologies allow for the high throughput screening (HTS) of large proprietary compound collections. However, the complexity of the assays utilized in HTS often results in a large number of hits that are then not confirmed in a subsequent secondary assay. It is now well accepted that for screening, quality is more important than quantity [Smith A. Nature 418, 453-459 (2002)]. Therefore, ways of making the biochemical assays for identification of new lead molecules more reliable are in continual development. - Over the last few years Nuclear Magnetic Resonance (NMR)-based screening has emerged as a powerful tool for lead molecule identification [Hajduk, P. J. et al. Quarterly Reviews of Biophysics 32, 211-240 (1999); Stockman, B. J. et al. Prog. NMR Spectr. 41, 187-231 (2002); Meyer, B. et al. Chem. Int. Ed. 42, 864 (2003)]. Although NMR has been applied extensively for characterizing the products of an enzymatic reaction or to gain insight into the kinetics of the reactions [Percival, M. D. & Withers, S. G. Biochemistry 31, 505-512 (1992)], NMR-based biochemical screening that measures the inhibition or the activation of an enzyme for the identification of new lead molecules has found limited applications [Chiyoda T. et al. Chem. Pharm. Bull. 46, 718-720 (1998)]. The low sensitivity limits NMR to enzymatic reactions with very high substrate concentration. Nonetheless, when NMR is compared to the other techniques utilized in HTS, it provides a more reliable array of data. NMR techniques monitor ligand binding to the receptor via the small molecule signals or the protein signals.
- Recent developments using 1H and in particular 19F NMR competition binding experiments have allowed for a reduction of substrate and protein consumption for the screening. In addition, these experiments provide with a single point measurement the value of the binding constant of the identified ligand. Percival and Withers used a NMR method to study binding of an enzyme to its fluorinated substrate analogues [Percival, M. D. & Withers, S. G. Biochemistry 31, 505-512 (1992)]. Such method utilizes 19F NMR detection and requires the presence of a fluorine atom on non-peptide substrates. The 19F signals of the starting and enzymatically transformed substrates are then monitored. Experiments can be performed in real time allowing the observed enzymatic activity to be monitored kinetically or in an endpoint assay format.
- In one aspect the present invention provides a method for identifying kinase inhibitors using NMR technology. In another aspect, the present invention provides kinase inhibitors identified by NMR technology.
- The present invention also provides a NMR method to characterize the unknown function of a protein by its interaction with CF3-labeled substrates of other known-function proteins.
-
FIG. 1 provides 19F 564 MHz NMR spectra for the CF3—CO N-capped-AKTide as a function of time (indicated in minutes) after the beginning of the enzymatic reaction. The activated protein, the peptide and ATP concentration were 50 nM, 30 μM and 131 μM, respectively. WtAKT1 recombinant protein was produced by infection of Sf21 insect cells with baculovirus coding for the full length protein fused to the GST moiety at the N-terminus and then purified to homogeneity after removal of the GST tag. The samples were in 50 mM Tris pH 7.5, with 1 mM DTT and 5 mM MgCl2. Spectra were recorded at 20° C. in the absence (FIG. 1A top) and in the presence (FIG. 1B bottom) of 10 μM Staurosporine. A total of 256 scans with 2.8 repetition time were recorded for each spectrum (12 minutes measuring time). Chemical shifts are referenced to trifluoroacetic acid. -
FIG. 2 provides (FIG. 2A top) 19F 564 MHz NMR spectra for the CF3—CO N-capped-AKTide recorded with three different concentrations (indicated in μM) for ATP. The activated protein and the peptide concentrations were 40 nM and 30 μM, respectively. The samples were in 50 mM Tris pH 7.5, with 1 mM DTT and 5 mM MgCl2. The reaction was run at 22° C. and quenched after 60 minutes with the addition of 10 μM staurosporine. (FIG. 2B bottom) Integral of the phosphorylated peptide as a function of the ATP concentration and the best fit of the experimental data with the derived KM for ATP of 89+/−17 μM. -
FIG. 3 provides (FIG. 3A top) 19F 564 MHz NMR spectra for the CF3—CO N-capped-AKTide recorded with three different concentrations (indicated in μM) for the inhibitor H89. The activated protein, the peptide and ATP concentration were 40 nM, 30 μM and 131 μM, respectively. The samples were in 50 mM Tris pH 7.5, with 1 mM DTT and 5 mM MgCl2. The reaction was run at 22° C. and quenched after 120 minutes with the addition of 10 μM staurosporine. (FIG. 3B bottom) Integral of the phosphorylated peptide as a function of the inhibitor concentration and the best fit of the experimental data with the derived IC50 for H89 of 0.72+/−0.05 μM. -
FIG. 4 provides the screening of proteases, where the substrate is the peptide of Seq ID NO:2 and the protein is trypsin from bovine pancreas. 19F NMR spectra for the peptide in the absence (a) and in the presence (b-e) of trypsin. The reaction was run at 22° C. and quenched after 30 minutes with the addition of 0.5 mM phenylmethylsulfonyl fluoride (PMSF). The reaction was performed in the absence of compound (b), in the presence of a five compound mixture (2-amino-6 methylquinazolin-4 ol, ethyl 2-quinoxalinecarboxylate, 5-methyl-benzimidazole, methyl isoquinoline-3-carboxylate, and leupeptin) (c), in the presence of the same mixture without leupeptin (d), and in the presence of only leupeptin (e). The protein, peptide, and compound concentrations were 15 nM, 30 μM, and 20 μM, respectively. A total of 128 scans with 2.8 s repetition time were recorded for each spectrum (6 minute measuring time). Pep and C-pep are the substrate and the product respectively. The asterisks in (c) and (e) indicate the chemical shift of the missing cleaved peptide signal. -
FIG. 5 provides the 19F spectra of the peptide of Seq ID NO:2 in the presence of three different proteins, 25 nM AKT1 (FIG. 5A top), 15 nM trypsin (FIG. 5B middle) and 150 nM PAK-4 (FIG. 5C bottom). The peptide is a good substrate for AKT1 and trypsin. The chemical shift of the cleaved peptide is quite different when compared to the chemical shift of the phosphorylated peptide. The reaction performed in the presence of p-21 activated protein PAK-4 results in the appearance of a signal at the chemical shift of the phosphorylated peptide. - The present invention overcomes the limitations of NMR biochemical screening with respect to protein and substrate concentrations when compared to prior art HTS techniques. The present invention provides a novel and sensitive NMR method in which a moiety with three fluorine atoms (CF3) is used to label a substrate. The use of a CF3-labeled substrate, e.g., a CF3-labeled peptide, allows for rapid and reliable biochemical screening at protein and substrate concentrations comparable to the concentrations utilized by standard HTS techniques. The NMR method of the present invention has unique advantages. i) Fluorine NMR spectroscopy is very sensitive, 0.83 times that of the proton. ii) Fluorine signals appear as sharp singlet resonances (the experiments do not require proton decoupling if the CF3 is not scalar coupled to protons) originating from three fluorine atoms, and therefore, the signal is very intense. This property is crucial for the screening because it permits the use of substrate concentrations that are in the range of its Km thus allowing detection of medium and weak inhibitors iii) There are no spectral interferences from protonated solvents, buffers, or detergents typically used in enzymatic reactions. Overlap with the signals of the substrate in the presence of the CF3-containing molecules represents an extremely rare event due to the limited number of sharp singlet 19F signals (molecules will typically have one CF3 group) and the large dispersion of the 19F chemical shift. iv) The 19F isotropic chemical shift is very sensitive to the chemical environment [Gerig, J. T. Prog. NMR Spectrosc. 26, 293-370 (1994)] resulting in differential chemical shifts for the starting and enzymatically transformed substrate resonances thus allowing a direct comparison of their intensities.
- In one embodiment of the present invention, NMR has been utilized to measure the phosphorylation of a CF3-labeled substrate by the protein Ser/Thr kinase AKT1. Protein kinase AKT1 is an anti-apoptotic protein kinase that has an elevated activity in a number of human malignancies [Staal, S. P. et al. J. Exp. Med. 167, 1259-1264 (1988); Bellacosa, A. Et al. Science 254, 274-277 (1991)]. The substrate AKTide is a peptide of 14 aminoacids [Obata, T. et al. J. Biol. Chem. 46, 36108-36115 (2000)] that was labeled with a CF3 moiety by N-terminal capping with trifluoroacetic anhydride resulting in the peptide (CF3—CO-ARKRERAYSFGHHA) (Seq ID NO:1). Alternatives can include the introduction of the CF3 group at the C-terminal via amide formation with a trifluoromethylamine or the substitution of one amino acid during the peptide synthesis with a fluorinated (CF3) amino acid (e.g. Tyr with para-CF3 Phe). The CF3 at the N terminal, the C terminal or the substituted amino acid (the para-CF3 Phe points toward the solvent, while the Ser to be phosphorylated points toward the enzyme), is located away from the serine phosphorylation site and therefore does not interfere with the binding. In the case of non-peptidic substrates, chemical synthesis is required for the introduction of the CF3 moiety in the appropriate position in the substrate.
- An enzymatic reaction was performed by incubating the unphosphorylated CF3-labeled peptide of Seq ID NO:1 in the presence of ATP and activated protein kinase AKT1. The conversion of unphosphorylated peptide to phosphorylated peptide generated a shift of the 19F signal as indicated in
FIG. 1 (top), which shows the 19F spectrum containing the signal of the CF3 moiety of the substrate as a function of time after the start of the enzymatic reaction. Attime 0 only one signal is observed corresponding to the unphosphorylated species of the peptide. With time the signal of the unphosphorylated peptide decreases and a new signal appears in the spectrum corresponding to the phosphorylated peptide. The sum of the two integral signals at any time after the start of the reaction corresponds to the signal integral of the unphosphorylated peptide attime 0. The enzymatic reaction is complete after 149 minutes and only the signal of the phosphorylated peptide is visible in the spectrum. - The same reaction performed in the presence of the strong inhibitor staurosporine did not result in any formation of phosphorylated peptide as is evident in
FIG. 1 (bottom). Despite the large distance of the CF3 group from the phosphorylation site, the chemical shifts of this moiety in the phosphorylated and unphosphorylated peptides are different. - As a screening method, the reaction can also be carried out in the presence of a mixture of compounds containing an inhibitor. Then, deconvolution of the active mixture is performed to identify which of the compounds in the mixture is the inhibitor. In accordance with the present invention, deconvolution means that the reaction is performed repeatedly in the presence of the mixture and in the absence of each one of the compounds. That is, there is no inhibition when the reaction in is carried out in the presence of the mixture minus the inhibitory compound. To confirm the inhibitory effect of one of the compounds, inhibition can be observed when the reaction is also performed in the presence of the single inhibitory compound that was identified from the mixture. As an example, the reaction of unphosphorylated CF3-labeled peptide of Seq ID NO:1, ATP, and activated protein kinase AKT1 was also performed in the presence of a five molecule mixture containing the compound H89 [Reuveni, H. et al. Biochemistry 41, 10304-10314 (2002)], an AKT1 inhibitor. The result was inhibition of peptide phosphorylation. There was no inhibition of peptide phosphorylation when this reaction was carried out in the presence of the mixture in the absence of H89. The inhibitory effect over peptide phosphorylation of H89 was confirmed when the reaction was performed in the presence of only H89.
- For screening purposes and IC50 measurements the reaction is typically stopped after an established delay that will depend on the enzyme and ATP concentrations and Kcat. The reaction can be quenched either by adding a concentrated solution of EDTA or by denaturating the protein. In accordance with the present invention, however, a more economical method is employed to quench reaction, namely the addition of about 5 to about 10 μM of the strong inhibitor staurosporine (IC50 in the low nM range). Even after several hours from the addition of staurosporine no changes of the 19F spectrum were observed. After the quench, the signal intensity ratio of the two 19F signals is monitored. In the absence of an inhibitor the signal intensity ratio I(p)/I(unP) corresponds to 0% inhibition whereas when the ratio is 0 it corresponds to 100% inhibition. This method is valid only if the peptide concentration is always the same otherwise the signal integral of the phosphorylated peptide should be monitored.
- The dissociation binding constant of ATP must be calculated first in order to optimize the ATP concentration used for the screening experiments and for deriving the binding constant of the hits from their IC50. For this purpose reactions at different ATP concentrations are recorded [Fersht, A. Enzyme Structure and Mechanism, W.H. Freeman and Company, New York 1985]. The signal intensity of the phosphorylated peptide as a function of the ATP concentration is shown in
FIG. 2 . Fitting of the experimental data results in a binding constant for ATP (in the presence of 30 μM substrate) of 89+/−17 μM. - In accordance with the present invention, screening is first performed at a single concentration for the compounds in the library. Compounds can be screened in small or large mixtures. For example, if only strong inhibitors with IC50<5 μM will be considered, then it will be sufficient to use molecules at about a 5 μM concentration. In practice, the reliability of the method of the present invention allows the identification of a weaker inhibitor with, e.g., an IC50 in the range of 10-20 μM even when the concentration of the screened molecules is only about 5 μM. As
FIG. 5 shows, substrate concentrations can be as low as about 10-20 nM. This low concentration allows the preparation of mixtures with a large number of components without severe problems of aggregation or solubility. Deconvolution of the active mixture is then carried out for the identification of the inhibitor. For the characterization of the IC50 of the hits, experiments at different inhibitor concentrations are then performed as shown inFIG. 3 for the compound H89 [Reuveni, H. et al. Biochemistry 41, 10304-10314 (2002)]. In the absence of allosteric effects a meaningful IC50 value is derived with a single point measurement. A CF3-labeled ATP analogue can also be used with the method of the present invention. In this case, the 19F signals of ATP and ADP are monitored. Inhibitors that bind in the ATP binding pocket or inhibitors that compete with the peptide for the substrate binding site can be identified. - The method of the present invention therefore represents a simple and reliable assay because it is homogeneous and directly detects both the phosphorylated and unphosphorylated substrate. The 19F NMR assay does not require i) the presence of secondary reactions performed with enzymes or specific antibodies or ii) separation and/or washing steps necessary for the readout with other methods. The method's simplicity results in reliable lead molecule identification and quantification of the molecules' inhibitory activity. Compounds displaying only a weak inhibitory activity can also be safely selected. Small chemical changes of the weak inhibitors or the selection of similar molecules bearing the same scaffold might result in the identification of potent inhibitors.
- In other art recognized HTS techniques, often the real concentration differs from the nominal concentration. A large difference in compound concentration results in a significant error of the derived IC50. The causes for concentration differences in other prior art HTS techniques can be ascribed to weighing errors, sample impurity, poor solubility of the compound, and chemical instability in an aqueous environment. In contrast, with the NMR method of the present invention these chemical properties can be easily measured by acquiring, in addition to the fluorine spectrum, also a proton spectrum. Therefore, the real concentration of the inhibitor determined with 1H NMR allows a significantly more accurate measurement of the IC50 value.
- The method of the present invention is not limited to the identification of inhibitors only, but can also be used for the detection of agonists. In the case of protein kinases the 19F signal of the phosphorylated peptide in the presence of an agonist is larger when compared to the same signal of the reference sample (i.e. sample for which the reaction was performed in the absence of compounds to be screened).
- The concentration of the protein used with this method can be as low as a few nanomolar, comparing favorably with the concentration used in other HTS techniques. However, the volume necessary for each NMR sample using a 5 mm probe is about 500-550 μL. A 2- to 3-fold volume reduction is achieved in accordance with the present invention with the use of a flow-injection probe or a 3 mm probe. The high sensitivity of the CF3 signal allows for rapid acquisition of the spectra. Further, the same spectra can be recorded even more rapidly with the use of cryogenic technology applied to 19F detection. Therefore, under the settings of the current method, the spectra that require an acquisition time of 3 minutes can be recorded in just 12 seconds. Further, the problems of radiation damping encountered in proton-detected experiments recorded with cryoprobes are absent in the fluorine-detected methodology of the present invention because of the low concentration of the CF3-labeled substrate.
- Bovine serum albumin (BSA) can be used with the method of the present invention to avoid sticking of the protein to the tube wall [Hlady, V. et al. Curr. Opin. Bioctechnol. 7, 72-77 (1996)]. However, while the enzymatic reaction in the presence of BSA becomes faster due to the fact that all the enzyme is available in solution, the IC50 of the compound can become weaker because of the compound sequestering from the solution by BSA. Therefore, the present method performed in the presence or absence of BSA or human serum albumin (HSA), for the compounds in the hit to lead optimization phase, can provide important structural information for designing analogues with retained inhibitory activity to the target enzyme and reduced affinity to albumin.
- The method of the present invention can also be applied to many different types and subtypes of enzymes (e.g. proteases, phosphatases, ligases, etc.). In another embodiment of the present invention, the screening can be performed with trypsin, a protease that cleaves peptide bonds C-terminally of lysine and arginine [Price, N. C. et al. Fundamentals of Enzymology, Oxford University Press, Oxford, U.K. (1999)], and, as a substrate, the peptide (ARKRERAF(3-CF3)SFGHHA) (Seq ID NO:2). As shown in
FIG. 4 b, in the presence of trypsin two 19F signals are visible in the spectrum at 13.38 and 13.33 ppm originating from the starting peptide and the cleaved peptide, respectively. Screening was performed in an end point assay format where the reaction was quenched after a defined delay using a known trypsin inhibitor (FIG. 4 c). Deconvolution of the active mixture was then performed for the identification of the inhibitor (FIGS. 4 d,e). Therefore, natural product extracts can be easily screened with this method. The components of the active extracts will then be separated via high performance liquid chromatography (HPLC) and tested as single compounds with the method of the present invention for the identification of the compound responsible for the inhibitory activity. - Another application of the method of the present invention is the determination of protein function. In view of the ready availability of high-throughput genome sequencing, thousands of proteins have been identified. However, the function of many of these proteins is unknown. The function of the protein can be inferred from the types of substrates that can be modified. For this purpose, a functional genomic library of CF3-labeled substrates of enzymes of known function is generated. These substrates are first tested on their known respective enzymes to determine the 19F chemical shifts of the starting and modified substrate. Some substrates can act as substrates for different classes of enzymes. This library of substrates is then screened as single compounds or in small mixtures against the protein with unknown function. The reduction in signal intensity of a 19F signal and the appearance of a new resonance at a defined chemical shift allows the recognition of the protein function.
- In another embodiment of the present invention, three different proteins, AKT1, Trypsin, and p-21 activated protein (PAK4) were incubated with the CF3-labeled peptide of Seq ID NO:2. As shown in
FIG. 5 , the reaction in the presence of PAK4 results in the appearance of a 19F signal with a chemical shift similar to the shift of a phosphorylated peptide as with the 19F signal of the reaction in the presence of AKT1. This result allowed for the classification of PAK4 to the kinase family. A higher concentration of the protein with unknown function and a longer incubation period may be required because the substrate may not be optimal for the protein with unknown function. The speed of the enzymatic reaction of PAK4 is only 1/22 of the speed of AKT1, therefore, the period of time for the reaction in the presence of PAK4 was longer than the period of time for the reaction in the presence of AKT1. The method of the present invention is also applicable to activated enzymes. - The method of the present invention extends the capabilities of NMR to the enzymatic reactions performed by Ser/Thr kinases. The method performs well and provides a reliable array of experimental data.
- WtAKT1 recombinant protein were produced by infection of sf21 insect cells with baculovirus coding for the full length protein fused to GST at the N-terminus. The cells were treated with okadaic acid for 4 hours prior to harvesting. This treatment, by inhibiting the cellular phosphatases, increaseed the total phosphorylation level of the protein leading to the phosphorylation of the two sites critical for AKT activity, threonine 308 in the activation loop and serine 473 in the C terminal hydrophobic motif. Lysis, purification, and removal of the GST tag were performed by following standard procedures. Trypsin, purchased from Roche Molecular Biochemical (Cat. No. 1418025), was dissolved in 1% acetic acid solution at a final stock solution concentration of 8.33 μM.
- The serine/threonine p21-activated kinase PAK4 was expressed as a GST fusion protein in Escherichia coli and purified to homogeneity after removal of the GST tag.
- All the compounds were prepared in DMSO stock solutions (20-40 nM). The peptides of Seq ID NO:1 and Seq ID NO:2 and Leupeptin were prepared in aqueous solutions at a concentration of 10 and 2.1 mM, respectively. The reactions were run in 50 mM Tris pH 7.5 with 1 mM DTT and 5 mM MgCl2 for AKT1 and 50 mM Tris pH 7.5 for trypsin. D2O was added to the solutions (8% final concentration) for the lock signal. The enzymatic reactions were performed at room temperature in Eppendorf vials and then quenched after a defined delay with the addition of staurosporine for AKT1 and PMSF for trypsin. The solutions were then transferred to 5 mm NMR tubes.
- All NMR spectra were recorded at 20° C. with a 600 NMR spectrometer operating at a 19F Larmor frequency of 564 MHZ. A 5 mm probe tunable to either 19F or 1H frequency was used. The instrument was equipped with a sample management system (SMS) autosampler for automatic data collection. The data were acquired without proton decoupling with an acquisition time of 0.8 seconds and a relaxation delay of 2.8 seconds. Chemical shifts are referenced to trifluoroacetic acid.
Claims (11)
1.-8. (canceled)
9. A method for characterizing the unknown function of an enzyme comprising:
a) Labeling a substrate of a known-function enzyme with a CF3-moiety;
b) Measuring a 19F signal shift for said CF3-labeled substrate in the presence of the activated known-function enzyme over a period of time whereby said period of time is the time length required for conversion of an unmodified CF3-labeled substrate into a modified CF3-labeled substrate by said known-function enzyme;
c) Measuring a 19F signal shift for said CF3-labeled substrate in the presence of an activated enzyme of unknown function over a period of time whereby said period of time is the time length required for conversion of an unmodified CF3-labeled substrate into a modified CF3-labeled substrate by said enzyme of unknown function and
d) Identifying the unknown function of the enzyme by comparing the 19F signal shifts measured in steps (b) and (c).
10. The method according to claim 9 , whereby the known-function enzyme is a kinase, a protease, a phosphatase, or a ligase.
11. A composition comprising a substrate of an enzyme labeled with a CF3-moiety.
12. The composition of claim 11 , further comprising said enzyme.
13. The composition of claim 12 , wherein said enzyme is selected from the group consisting of a kinase, a protease, a phosphatase, and a ligase.
14. The composition of claim 12 , further comprising an inhibitor of said enzyme.
15. The composition of claim 14 , wherein said enzyme is a kinase.
16. The composition of claim 12 , further comprising an agonist of said enzyme.
17. The composition of claim 16 , wherein said enzyme is a kinase.
18. The composition of claim 11 , wherein said substrate is a substrate of an known-function enzyme, and wherein said composition further comprises an activated enzyme of unknown function.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/825,779 US20080233603A1 (en) | 2003-07-10 | 2007-07-09 | Fluorine NMR spectroscopy for biochemical screening |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48609903P | 2003-07-10 | 2003-07-10 | |
US10/888,378 US7255985B2 (en) | 2003-07-10 | 2004-07-09 | Fluorine NMR spectroscopy for biochemical screening |
US11/825,779 US20080233603A1 (en) | 2003-07-10 | 2007-07-09 | Fluorine NMR spectroscopy for biochemical screening |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/888,378 Division US7255985B2 (en) | 2003-07-10 | 2004-07-09 | Fluorine NMR spectroscopy for biochemical screening |
Publications (1)
Publication Number | Publication Date |
---|---|
US20080233603A1 true US20080233603A1 (en) | 2008-09-25 |
Family
ID=34062114
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/888,378 Expired - Fee Related US7255985B2 (en) | 2003-07-10 | 2004-07-09 | Fluorine NMR spectroscopy for biochemical screening |
US11/825,779 Abandoned US20080233603A1 (en) | 2003-07-10 | 2007-07-09 | Fluorine NMR spectroscopy for biochemical screening |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/888,378 Expired - Fee Related US7255985B2 (en) | 2003-07-10 | 2004-07-09 | Fluorine NMR spectroscopy for biochemical screening |
Country Status (10)
Country | Link |
---|---|
US (2) | US7255985B2 (en) |
EP (1) | EP1644512B1 (en) |
JP (1) | JP4566192B2 (en) |
AT (1) | ATE408021T1 (en) |
BR (1) | BRPI0412501A (en) |
CA (1) | CA2531339C (en) |
DE (1) | DE602004016512D1 (en) |
ES (1) | ES2313025T3 (en) |
MX (1) | MXPA06000360A (en) |
WO (1) | WO2005005978A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1923397B1 (en) | 2006-11-14 | 2009-10-28 | NERVIANO MEDICAL SCIENCES S.r.l. | Fluorinated amino acids and peptides |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5698401A (en) * | 1995-11-14 | 1997-12-16 | Abbott Laboratories | Use of nuclear magnetic resonance to identify ligands to target biomolecules |
-
2004
- 2004-07-09 US US10/888,378 patent/US7255985B2/en not_active Expired - Fee Related
- 2004-07-12 CA CA2531339A patent/CA2531339C/en not_active Expired - Fee Related
- 2004-07-12 AT AT04740926T patent/ATE408021T1/en active
- 2004-07-12 BR BRPI0412501-0A patent/BRPI0412501A/en not_active IP Right Cessation
- 2004-07-12 ES ES04740926T patent/ES2313025T3/en not_active Expired - Lifetime
- 2004-07-12 WO PCT/EP2004/007672 patent/WO2005005978A2/en active IP Right Grant
- 2004-07-12 MX MXPA06000360A patent/MXPA06000360A/en active IP Right Grant
- 2004-07-12 DE DE602004016512T patent/DE602004016512D1/en not_active Expired - Lifetime
- 2004-07-12 JP JP2006518173A patent/JP4566192B2/en not_active Expired - Fee Related
- 2004-07-12 EP EP04740926A patent/EP1644512B1/en not_active Expired - Lifetime
-
2007
- 2007-07-09 US US11/825,779 patent/US20080233603A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2005005978A2 (en) | 2005-01-20 |
US20050048594A1 (en) | 2005-03-03 |
MXPA06000360A (en) | 2006-03-28 |
CA2531339A1 (en) | 2005-01-20 |
EP1644512A2 (en) | 2006-04-12 |
DE602004016512D1 (en) | 2008-10-23 |
US7255985B2 (en) | 2007-08-14 |
ES2313025T3 (en) | 2009-03-01 |
EP1644512B1 (en) | 2008-09-10 |
BRPI0412501A (en) | 2006-09-19 |
ATE408021T1 (en) | 2008-09-15 |
JP2009501312A (en) | 2009-01-15 |
JP4566192B2 (en) | 2010-10-20 |
CA2531339C (en) | 2013-04-02 |
WO2005005978A3 (en) | 2005-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Dalvit | Ligand-and substrate-based 19F NMR screening: Principles and applications to drug discovery | |
Dalvit et al. | A general NMR method for rapid, efficient, and reliable biochemical screening | |
EP1175508B1 (en) | Optical probes and assays for measuring protein phosphorylation | |
US8124343B2 (en) | IRE-1α substrates | |
Fejzo et al. | Application of NMR screening in drug discovery | |
Fernández et al. | New approaches for NMR screening in drug discovery | |
Dalvit et al. | Fluorine NMR functional screening: from purified enzymes to human intact living cells | |
CA2483688A1 (en) | Methods for measuring kinase activity and phosphatase activity | |
US7255985B2 (en) | Fluorine NMR spectroscopy for biochemical screening | |
Dalvit et al. | Rapid NMR‐based functional screening and IC50 measurements performed at unprecedentedly low enzyme concentration | |
Clarke et al. | Fluorescent carbazole-derived α-amino acids: structural mimics of tryptophan | |
Viht et al. | Fluorometric TLC assay for evaluation of protein kinase inhibitors | |
JP4615867B2 (en) | Method for measuring protein kinase and phosphatase activities | |
Zhang et al. | Selectively 2H‐labeledGlu/Asp: application to pKa measurements in Aβ amyloid peptides | |
Monasterio et al. | Tubulin-tyrosine ligase catalyzes covalent binding of 3-fluoro-tyrosine to tubulin: kinetic and [19F] NMR studies | |
US20020164620A1 (en) | Method for identifying compounds modulating sister chromatid separation | |
Dalvit | Fluorine NMR spectroscopy for biochemical screening in drug discovery | |
EP3076175A1 (en) | Detection and quantification of o-acetyl-adp-ribose as a readout system for measuring the activity of e.g. sirtuins | |
CA2380238A1 (en) | Homogeneous fluorescence method for assaying structural modifications of biomolecules | |
MENEGATTI et al. | Controlled proteolysis of mouse epidermal growth factor An RP‐HPLC and 1H‐nmr study | |
KR100901309B1 (en) | How to Select a Compound That Binds to an Active Site of a Protein | |
US8080235B2 (en) | Protein kinase A reporters useful in high throughput assays | |
JP3015886B1 (en) | A rapid method for the determination of asparagine residue-specific endoprotease activity from plants | |
CN115505030A (en) | Fluorescent probe for TMPRSS2 protease detection and inhibitor screening, preparation method and application thereof | |
Rout et al. | Characterization of self-templating catalytic amyloids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |